I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Dara Azar maintained a Buy rating on Enliven Therapeutics today and set a price target of $82.00.
According to TipRanks, Azar is an analyst with an average return of -4.7% and a 28.57% success rate. Azar covers the Healthcare sector, focusing on stocks such as Enliven Therapeutics, Summit Therapeutics, and Immunome.
In a report released today, Barclays also maintained a Buy rating on the stock with a $78.00 price target.
